Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. (Q37724195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

review article

1 reference

title

Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Lalit S Doshi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Umakant A Bahirat

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Amol V Dixit

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Kumar V S Nemmani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

language of work or name

English

0 references

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

489-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20367191%20AND%20SRC:MED&resulttype=core&format=json

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A review of rosiglitazone in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Thiazolidinediones, insulin resistance and obesity: Finding a balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Possible heart failure exacerbation associated with rosiglitazone: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Redefining the role of thiazolidinediones in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Safety issues and prospects for future generations of PPAR modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

INT131: a selective modulator of PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Partial agonists activate PPARgamma using a helix 12 independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Transcription coactivators for peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Nuclear receptor corepressors and PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Activation of PPARgamma coactivator-1 through transcription factor docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Metabolic control through the PGC-1 family of transcription coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PPAR gamma partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

What has prevented the expansion of insulin sensitisers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Benzoyl 2-methyl indoles as selective PPARgamma modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Recent findings concerning thiazolidinediones in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Terminal differentiation of human breast cancer through PPAR gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

PPAR gamma signaling exacerbates mammary gland tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Discovery of a novel class of PPARdelta partial agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Selective PPARgamma modulators with improved pharmacological profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169

Thiazolidinediones and Heart Failure: A teleo-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003640169